Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
703 (USA) · Dr. Okafor
consented 2013-10-25
Adverse events
Mild APPLICATION SITE DERMATITIS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-11-23 (study day 30.0); relationship: PROBABLE
Mild APPLICATION SITE PRURITUS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-11-23 (study day 30.0); relationship: PROBABLE
Moderate APPLICATION SITE PRURITUS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-11-23 (study day 30.0); relationship: PROBABLE
Moderate BENIGN PROSTATIC HYPERPLASIA — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-11-20 (study day 27.0); relationship: NONE
Moderate BIOPSY PROSTATE — outcome: RECOVERED/RESOLVED; onset 2013-11-16 (study day 23.0); relationship: NONE
Moderate HYPERCHOLESTEROLAEMIA — outcome: NOT RECOVERED/NOT RESOLVED; onset 2007; relationship: NONE
Mild HYPERHIDROSIS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-11-25 (study day 32.0); relationship: POSSIBLE
Data queries
No data queries.